KR20130097211A - 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 - Google Patents

오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 Download PDF

Info

Publication number
KR20130097211A
KR20130097211A KR1020137010558A KR20137010558A KR20130097211A KR 20130097211 A KR20130097211 A KR 20130097211A KR 1020137010558 A KR1020137010558 A KR 1020137010558A KR 20137010558 A KR20137010558 A KR 20137010558A KR 20130097211 A KR20130097211 A KR 20130097211A
Authority
KR
South Korea
Prior art keywords
naltrexone
opioid
formulation
respiratory depression
oxycodone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137010558A
Other languages
English (en)
Korean (ko)
Inventor
마이클 제이. 람슨
비레인다르 골리
Original Assignee
알파마 파머슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알파마 파머슈티컬스 엘엘씨 filed Critical 알파마 파머슈티컬스 엘엘씨
Publication of KR20130097211A publication Critical patent/KR20130097211A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137010558A 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법 Ceased KR20130097211A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40675210P 2010-10-26 2010-10-26
US61/406,752 2010-10-26
PCT/IB2011/054767 WO2012056402A2 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167003000A Division KR20160017668A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법

Publications (1)

Publication Number Publication Date
KR20130097211A true KR20130097211A (ko) 2013-09-02

Family

ID=45470606

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137010558A Ceased KR20130097211A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
KR1020167003000A Ceased KR20160017668A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
KR1020177024247A Ceased KR20170102571A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167003000A Ceased KR20160017668A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
KR1020177024247A Ceased KR20170102571A (ko) 2010-10-26 2011-10-25 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법

Country Status (14)

Country Link
US (3) US20140030343A1 (https=)
EP (1) EP2632442A2 (https=)
JP (1) JP2013540807A (https=)
KR (3) KR20130097211A (https=)
CN (1) CN103189055A (https=)
AU (1) AU2011322147A1 (https=)
BR (1) BR112013009267A2 (https=)
CA (1) CA2814230A1 (https=)
IL (1) IL225966A0 (https=)
MX (1) MX2013003832A (https=)
RU (1) RU2541159C2 (https=)
SG (1) SG189234A1 (https=)
WO (1) WO2012056402A2 (https=)
ZA (1) ZA201302363B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
RU2541159C2 (ru) * 2010-10-26 2015-02-10 АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов
BR112013019431A2 (pt) * 2011-02-02 2020-10-27 Alpharma Pharmaceuticals, Llc composição farmacêutica compreendendo agonista opioide e antagonista sequestrado
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) * 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
WO2021072055A1 (en) * 2019-10-11 2021-04-15 Board Of Regents, The University Of Texas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
US20230063876A1 (en) * 2020-03-02 2023-03-02 Unm Rainforest Innovations Virus-Like Particle Vaccines for Opioid Drugs
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
KR20240101622A (ko) * 2021-11-02 2024-07-02 에날레어 테라퓨틱스 인크. 비아편유사제에 의해 조절되는 호흡 억제의 치료 방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160222A0 (en) * 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
WO2005056087A1 (en) * 2003-12-05 2005-06-23 Cardinal Health 303, Inc. Patient-controlled analgesia with patient monitoring system
US8168447B2 (en) 2005-10-07 2012-05-01 University Of Florida Research Foundation, Inc. Multiple component nanoparticles for multiplexed signaling and optical encoding
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
EP2197427A2 (en) * 2007-09-04 2010-06-23 Alpharma, Inc. A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
IT1391530B1 (it) 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
CN102231991A (zh) 2008-07-31 2011-11-02 生物工程大学精神物质实验室 应用于生物分析的活性粒子及其制备方法
RU2541159C2 (ru) * 2010-10-26 2015-02-10 АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов

Also Published As

Publication number Publication date
JP2013540807A (ja) 2013-11-07
AU2011322147A1 (en) 2013-04-18
SG189234A1 (en) 2013-05-31
WO2012056402A2 (en) 2012-05-03
KR20160017668A (ko) 2016-02-16
US20170367987A1 (en) 2017-12-28
CN103189055A (zh) 2013-07-03
BR112013009267A2 (pt) 2016-07-26
MX2013003832A (es) 2013-10-01
RU2541159C2 (ru) 2015-02-10
WO2012056402A3 (en) 2012-10-04
EP2632442A2 (en) 2013-09-04
KR20170102571A (ko) 2017-09-11
US20140030343A1 (en) 2014-01-30
ZA201302363B (en) 2014-06-25
CA2814230A1 (en) 2012-05-03
IL225966A0 (en) 2013-06-27
US20160045449A1 (en) 2016-02-18
RU2013117274A (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
KR20130097211A (ko) 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
US20210000819A1 (en) Abuse resistant transmucosal drug delivery device
US8623418B2 (en) Pharmaceutical composition
US20130122065A1 (en) Pharmaceutical Composition
US20150104519A1 (en) Pharmaceutical Compositions
CA2709950A1 (en) Pharmaceutical composition
US20240408078A1 (en) Method of treatment and dosage forms thereof
AU2008338439A1 (en) Pharmaceutical composition
AU2019201397A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
HK1186970A (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
AU2014216032B2 (en) Pharmaceutical composition
AU2019202760A1 (en) Pharmaceutical composition
AU2014216026A1 (en) Pharmaceutical composition
AU2012250609A1 (en) Methods for detecting enhanced risk of opioid-induced hypoxia in a patient

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20130425

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140730

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150623

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140730

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20150623

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20150130

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130425

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20151102

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150924

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20150623

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150130

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20140730

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20130425

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160202